Federazione Italiana Aziende Sanitarie e Ospedaliere, Scuola di Specializzazione in Statistica Sanitaria, Università di Roma La Sapienza, Rome, Italy.
Obes Surg. 2012 Apr;22(4):646-53. doi: 10.1007/s11695-012-0608-1.
Bariatric surgery is to date the most effective treatment for morbid obesity and it has been proven to reduce obesity-related comorbidities and total mortality. As any medical treatment, bariatric surgery is costly and doubts about its affordability have been raised. On the other hand, bariatric surgery may reduce the direct and indirect costs of obesity and related comorbidities. The appreciation of the final balance between financial investments and savings is critical from a health economic perspective. In this paper, we try to provide a brief updated review of the most recent studies on the cost-efficacy of bariatric surgery, with particular emphasis on budget analysis. A brief overview of the economic costs of obesity will also be provided. The epidemic of obesity may cause a significant reduction in life expectancy and overwhelming direct and indirect costs for citizens and societies. Cost-efficacy analyses included in this review consistently demonstrated that the additional years of lives gained through bariatric surgery may be obtained at a reasonable and affordable cost. In groups of patients with very high obesity-related health costs, like patients with type 2 diabetes, the use of bariatric surgery required an initial economic investment, but may save money in a relatively short period of time.
肥胖症手术是目前为止治疗病态肥胖症最有效的方法，已被证明可减少肥胖相关的合并症和总死亡率。和任何医疗手段一样，肥胖症手术费用高昂，因此人们对其是否负担得起产生了质疑。另一方面，肥胖症手术可能会降低肥胖症及其相关合并症的直接和间接成本。从健康经济学的角度来看，评估金融投资和储蓄的最终平衡至关重要。本文尝试简要综述肥胖症手术成本效益的最新研究，重点是预算分析。此外，还将简要概述肥胖症的经济成本。肥胖症的流行可能导致预期寿命显著缩短，并给公民和社会带来巨大的直接和间接成本。本综述中的成本效益分析一致表明，通过肥胖症手术获得的额外寿命可以以合理且可承受的成本获得。在肥胖相关健康成本非常高的患者群体中，例如 2 型糖尿病患者，使用肥胖症手术需要初始经济投资，但可能会在相对较短的时间内节省资金。
